Making a key ruling in a long-running battle over lucrative patent rights, a government patent board has knocked down the University of California’s initial claims that its scientists turned CRISPR into a genome editor in plant and animal cells in 2012, threatening its effort to secure patents on the groundbreaking technology.

The decision from the Patent Trial and Appeal Board comes in an ongoing dispute over who first invented the use of CRISPR genome editing in eukaryotic cells (animal and plant cells, not bacteria or DNA floating in a test tube). It’s the latest turn in a years long and at times nasty battle between the Broad Institute of Cambridge, Mass., and UC and its partners, the University of Vienna and scientist Emmanuelle Charpentier (collectively known in the case as CVC).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy